洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

首页 临床进展 The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.

【ChiCTR2300079249】The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.

查看原文
立即下载
基本信息
登记号

ChiCTR2300079249

试验状态

正在进行

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2023-12-28

临床申请受理号

/

靶点

/

适应症

Non-Alcoholic fatty liver diseases with type 2 diabetes mellitus

试验通俗题目

The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.

试验专业题目

The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

The aim and objective of this study is to evaluate the effect of ertugliflozin on Non alcoholic fatty liver diseases patients with type 2 diabetes mellitus along with its impact on the function of liver enzymes. The purpose of the study is to determine the effect of ertugliflozin, pioglitazone, and metformin in the improvement of nonalcoholic fatty liver diseases with type 2 diabetes mellitus. Other outcomes include improvement in an elevated liver enzyme and blood cholesterol as well as a change in the quality of life of the patient.

试验分类
请登录查看
试验类型

随机平行对照

试验分期

探索性研究/预试验

随机化

Computer generated randomization. The participants will be randomized into three groups. The random technique will be used form a list of random numbers obtained from computer of eligible patients which will be compiled by using the patients’ hospital identification numbers.

盲法

Blinded (masking used). The study is double blinded nether the participant know and nether the experimenter or investigator knows.

试验项目经费来源

自筹

试验范围

/

目标入组人数

60

实际入组人数

/

第一例入组时间

2024-01-01

试验终止时间

2024-08-31

是否属于一致性

/

入选标准

Participants for this randomize control trail must be Adult patients with age above 20 years and less than 70 years diagnosed with non alcoholic fatty liver diseases along with type 2 diabetes mellitus.；

排除标准

Participants not having non alcoholic fatty liver diseases along with type 2 diabetes mellitus, not willing to participate and the patient having elevated liver enzyme with any other risk factor such as hepatitis or other viral infection.；

研究者信息
研究负责人姓名
请登录查看
试验机构

ADIL KHALIQ

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

ADIL KHALIQ的其他临床试验

更多

DEPARTMENT OF PHARMACY ABDUL WALI KHAN UNIVERSITY MARDAN KYBERPAKHTUNKHWA PAKISTAN的其他临床试验

更多

最新临床资讯

更多
摩熵医药企业版
50亿+条医药数据随时查
7天免费试用
体验产品